Möller H J, Riehl T, Dietzfelbinger T, Wernicke T
Psychiatric Clinic, University of Bonn, Venusberg, Germany.
Int Clin Psychopharmacol. 1991 Winter;6(3):179-92. doi: 10.1097/00004850-199100630-00006.
Efficacy and tolerability of mianserin (60-90 mg/day) or maprotiline (100-150 mg/day) were tested in a 4-week double-blind control group study on 317 depressive outpatients. The patients had to fulfill the criteria of a major depression according to DSM-III. The study was performed by psychiatrists after special rater training. Standardized rating procedures were applied to evaluate depressive symptoms and unwanted effects at three measurement points. A significant improvement was found in both groups, without any statistical differences between mianserin and maprotiline. According to the Clinical Global Impressions (CGI) 65% of the patients in both groups were judged as responders. A good tolerability of both drugs were demonstrated. With respect to anticholinergic side-effects there was a certain advantage in favor to mianserin.
在一项针对317名门诊抑郁症患者的为期4周的双盲对照组研究中，测试了米安色林（60 - 90毫克/天）或马普替林（100 - 150毫克/天）的疗效和耐受性。这些患者必须符合美国精神疾病诊断与统计手册第三版（DSM - III）中重度抑郁症的标准。该研究由经过特殊评分员培训的精神科医生进行。在三个测量点采用标准化评分程序来评估抑郁症状和不良反应。两组均有显著改善，米安色林和马普替林之间无任何统计学差异。根据临床总体印象量表（CGI），两组中65%的患者被判定为有反应者。两种药物均显示出良好的耐受性。在抗胆碱能副作用方面，米安色林有一定优势。
